dexrazoxane has been researched along with Cardiac Failure in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelfattah, OM; Abela, GS; Addison, D; Awad, AK; Barac, A; Fradley, MG; Gerew, M; Ghaith, HS; Guha, A; Moustafa, K; Munir, M; Sayed, A; Shazly, O | 1 |
| Armenian, S; de Baat, EC; Feijen, EA; Grotenhuis, H; Hudson, MM; Kremer, LC; Mavinkurve-Groothuis, AM; Mulder, RL; van Dalen, EC | 1 |
| Corrêa, FM; Fernandes, RRA; Freitas, PG; Guerra, RL; Vianna, CMM | 1 |
| Brion, A; Cahn, JY; Daguindau, E; Deconinck, E; Limat, S; Nerich, V; Perrin, S; Woronoff-Lemsi, MC | 1 |
| Franco, VI; Lipshultz, SE | 1 |
| Abdel-Qadir, H; Amir, E; Fazelzad, R; Lee, DS; Ong, G; Thavendiranathan, P; Tomlinson, G | 1 |
4 review(s) available for dexrazoxane and Cardiac Failure
| Article | Year |
|---|---|
Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bayes Theorem; Cardiotoxicity; Dexrazoxane; Female; Heart Failure; Humans; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Network Meta-Analysis; Stroke Volume; Ventricular Function, Left | 2022 |
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Heart Failure; Humans; Leukemia, Myeloid, Acute; Polyketides; Systematic Reviews as Topic | 2022 |
Cardiac complications in childhood cancer survivors treated with anthracyclines.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Heart Failure; Humans; Neoplasms; Pediatrics; Risk Factors; Survivors | 2015 |
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Cardiomyopathies; Clinical Trials as Topic; Dexrazoxane; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Network Meta-Analysis; Prenylamine; Ventricular Dysfunction, Left | 2017 |
2 other study(ies) available for dexrazoxane and Cardiac Failure
| Article | Year |
|---|---|
[Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines].
Topics: Age Factors; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Cost-Benefit Analysis; Dexrazoxane; Female; Heart; Heart Failure; Humans; Male; Neoplasms | 2019 |
Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cardiotonic Agents; Cyclophosphamide; Dexrazoxane; Doxorubicin; Female; Heart Failure; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Prednisone; Retrospective Studies; Risk Factors; Rituximab; Vincristine; Young Adult | 2014 |